[go: up one dir, main page]

WO2005067460A3 - Epha2 vaccines - Google Patents

Epha2 vaccines Download PDF

Info

Publication number
WO2005067460A3
WO2005067460A3 PCT/US2004/034693 US2004034693W WO2005067460A3 WO 2005067460 A3 WO2005067460 A3 WO 2005067460A3 US 2004034693 W US2004034693 W US 2004034693W WO 2005067460 A3 WO2005067460 A3 WO 2005067460A3
Authority
WO
WIPO (PCT)
Prior art keywords
epha2
methods
cancer
autologous
antigenic peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/034693
Other languages
French (fr)
Other versions
WO2005067460A2 (en
Inventor
Michael S Kinch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to EP04809990A priority Critical patent/EP1732580A4/en
Publication of WO2005067460A2 publication Critical patent/WO2005067460A2/en
Anticipated expiration legal-status Critical
Publication of WO2005067460A3 publication Critical patent/WO2005067460A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly metastatic cancer, and hyperproliferative diseases involving EphA2-expressing cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of an EphA2 antigenic peptide to elicit an immune response against the EphA2-expressing cells. In other embodiments, the methods of the invention entail the use of an EphA2 expression vehicle, such as a naked nucleic acid or viral vector. In yet other embodiments, the methods of the invention comprise the use of adoptive immunotherapy with autologous or non-autologous antigen presenting cells that are sensitized with one or more EphA2 antigenic peptides. The invention also provides pharmaceutical compositions comprising one or more EphA2 antigenic peptides, expression vehicles or antigen-presenting cells of the invention either alone or in combination with one or more other agents useful for cancer therapy.
PCT/US2004/034693 2003-12-24 2004-10-15 Epha2 vaccines Ceased WO2005067460A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04809990A EP1732580A4 (en) 2003-12-24 2004-10-15 Epha2 vaccines

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US53269603P 2003-12-24 2003-12-24
US60/532,696 2003-12-24
US60258804P 2004-08-18 2004-08-18
US60/602,588 2004-08-18
US61554804P 2004-10-01 2004-10-01
US60/615,548 2004-10-01
US61756404P 2004-10-07 2004-10-07
US60/617,564 2004-10-07

Publications (2)

Publication Number Publication Date
WO2005067460A2 WO2005067460A2 (en) 2005-07-28
WO2005067460A3 true WO2005067460A3 (en) 2006-10-26

Family

ID=34799812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/034693 Ceased WO2005067460A2 (en) 2003-12-24 2004-10-15 Epha2 vaccines

Country Status (2)

Country Link
EP (1) EP1732580A4 (en)
WO (1) WO2005067460A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691393B2 (en) 2003-02-06 2010-04-06 Anza Therapeutics, Inc. Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the Listeria, and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
US12514944B2 (en) 2019-06-22 2026-01-06 Cerus Corporation Systems and methods for implementing treatment of biological fluids

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 and non-neoplastic hyperproliferative cell disorders
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
US20120052080A1 (en) 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
KR101557169B1 (en) 2007-05-18 2015-10-02 메디뮨 엘엘씨 Preservation of living materials by freeze-dried foam
KR101561416B1 (en) 2007-08-30 2015-10-16 다이이찌 산쿄 가부시키가이샤 Anti-epha2 antibody
CN103237901B (en) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 For treating the biomarker of diagnosis
JP2013526852A (en) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Circulating biomarkers for disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4557714B2 (en) * 2002-05-10 2010-10-06 メディミューン，エルエルシー EphA2 monoclonal antibody and method of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUXBURY ET AL.: "Ligation of EphA2 by Ephrin A1-Fc Inhibits Pancreatic Adenocarcinoma Cellular Invasiveness", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 320, no. 4, August 2004 (2004-08-01), pages 1096 - 1102, XP027194341, DOI: doi:10.1016/j.bbrc.2004.06.054 *
HATANA ET AL.: "EphA2 as a Glioma-Associated Antigen: A Novel Target for Glioma Vaccines", NEOPLASIA, vol. 7, no. 8, August 2005 (2005-08-01), pages 717 - 722, XP008076099, DOI: doi:10.1593/neo.05277 *
HATANA ET AL: "Vaccination with EphA2-Derived T Cell-Epitopes Promotes Immunity Against Both EphA2-Expression and EphA2-Negative Tumors", J. TRANSL. MED., vol. 2, no. 1, November 2004 (2004-11-01), pages 40, XP021018960, DOI: doi:10.1186/1479-5876-2-40 *
WYKOSKY ET AL.: "EphA2 as a Novel Molecular Marker and Target in Glioblastoma Multiforme", MOL. CANCER RES., vol. 3, no. 10, October 2005 (2005-10-01), pages 541 - 551, XP008076096, DOI: doi:10.1158/1541-7786.MCR-05-0056 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691393B2 (en) 2003-02-06 2010-04-06 Anza Therapeutics, Inc. Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the Listeria, and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7927606B2 (en) 2003-02-06 2011-04-19 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US12514876B2 (en) 2015-06-26 2026-01-06 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
US12064537B2 (en) 2017-03-03 2024-08-20 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US12214092B2 (en) 2017-12-29 2025-02-04 Cerus Corporation Systems and methods for treating biological fluids
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US12514944B2 (en) 2019-06-22 2026-01-06 Cerus Corporation Systems and methods for implementing treatment of biological fluids
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12343436B2 (en) 2019-06-28 2025-07-01 Cerus Corporation System and methods for implementing a biological fluid treatment device

Also Published As

Publication number Publication date
WO2005067460A2 (en) 2005-07-28
EP1732580A2 (en) 2006-12-20
EP1732580A4 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
WO2005067460A3 (en) Epha2 vaccines
De Titta et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose
WO2007028574A3 (en) Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
WO2006037421A3 (en) Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
WO2010037514A3 (en) Novel immunotherapy against several tumors including neuronal and brain tumors
CR20200562A (en) PEPTIDES AND PEPTID COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST NON-HADGKINIAN LYMPHOMA (NHL) AND OTHER TYPES OF CANCER (Divisional 2018-0346)
WO2011113819A3 (en) Diagnosis and treatment of cancer based on avl9
MX2009001412A (en) Protein matrix vaccines and methods of making and administering such vaccines.
HK1244666A1 (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
DE60229979D1 (en)
UA97095C2 (en) Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine
WO2007130555A3 (en) Augmentation of immune response to cancer vaccine
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2002053176A3 (en) An autologous anti-cancer vaccine
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2003093298A3 (en) Immunogenic peptides
ES2965333T3 (en) DNA vaccines and rejection prevention procedures after a transplant
Smith et al. Immunotherapy in cancer treatment
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2011090266A3 (en) Novel tumor antigen protein agr2 and tumor antigenic peptide thereof
EA202190186A1 (en) PEPTIDES, COMBINATIONS OF PEPTIDES AND CELL-BASED MEDICINES FOR USE IN IMMUNOTHERAPY OF BLADDER CANCER AND OTHER TYPES OF CANCER
EA202191120A3 (en) PEPTIDES AND THEIR COMBINATIONS FOR USE IN CANCER IMMUNOTHERAPY
EA201992860A1 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN LUNG CANCER IMMUNOTHERAPY, INCLUDING NON-SMALL CELL LUNG CANCER (NSCLC), SMALL-CELL LUNG CANCER (MRL) AND OTHER
EA202190465A3 (en) NEW PEPTIDES AND PEPTIDE COMBINATIONS FOR USE IN NHL IMMUNOTHERAPY AND OTHER CANCER

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2004809990

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2004809990

Country of ref document: EP